The grant, stated plainly. On February 18, 2025, Astellas Pharma was issued US12227586B2, covering an anti-CLDN4/anti-CD137 bispecific antibody. The CPC tags — C07K 16/2878, C07K 16/28, A61P 35/00 (antineoplastic), plus the C07K 2317 engineering series — describe a construct that bridges a tumor antigen (claudin-4) to a T-cell costimulatory receptor (CD137/4-1BB).
Why an event-driven desk notes the target pairing: a bispecific that pairs a tumor antigen with a costimulatory receptor is designed to switch on immune activation specifically at the tumor, limiting systemic toxicity. The choice of CLDN4 as the tumor anchor is a specific bet on a target with defined expression — and clinical readouts are what test it.
The disciplined read: a bispecific construct grant is an exclusivity claim on a specific binder pairing and format, not a clinical outcome. The business stakes ride on whether the localized-activation design delivers a better therapeutic window in patients — answered by data, not the patent.
What the grant does not say: nothing about efficacy, safety, or approval, and nothing about freedom from competing CD137-engager estates. Those are separate facts in separate records.
The takeaway: when scanning bispecific programs, read the target pairing to understand each construct's design bet. Astellas' February 2025 CLDN4xCD137 grant is a dated example of a tumor-localized-activation approach.